Early Diagnosis of Premature Births by Analysis of the Vaginal Microbiota

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Feb 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the bacteria in the vagina, known as vaginal microbiota, can help predict premature births in pregnant women who are at risk. The researchers are using a special computer program that analyzes genetic information from these bacteria to see if it can accurately indicate whether a woman might have her baby early. By understanding the vaginal microbiota better, the hope is to improve early diagnosis and care for women facing this serious issue.

To participate in the trial, women must be at least 14 weeks pregnant and admitted to the Clermont-Ferrand University Hospital maternity ward with signs that they might deliver early, such as contractions or changes in the cervix. They should also be willing to provide a vaginal swab for testing and be covered by French social security. Participants can expect to have their vaginal bacteria analyzed over time and will contribute to important research that could help improve the health outcomes for both mothers and their babies. It’s important to note that women who have recently taken antibiotics or are under legal guardianship cannot join this study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women Admitted to the Clermont-Ferrand University Hospital maternity ward from 14 weeks' gestation onwards
• • For threat of preterm birth (PTB) characterized by contractile activity and/or cervical changes, or for premature rupture of fetal membranes (PROM)
• • And in need of vaginal swabbing
• • Single or multiple pregnancy
• • Able to understand and object to the study
• • Covered by a French social security scheme.
• • Give informed consent for the study
• Exclusion Criteria:
• • Patient under guardianship, curatorship or safeguard of justice
• • Patient having received antibiotic therapy in the 2 weeks prior to admission